Related Experiment Video
Updated: Feb 6, 2026
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
[Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report]
O V Boyko1, I I Khoroshylova2, S V Petrov2
1Pirogov Russian National Research Medical University, Moscow, Russia; OOO 'Neuroclinica', Moscow, Russia.
Abstract:
Anti-B-cells products, including the anti-CD20 monoclonal antibody ocrelizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) was proved by three phase III clinical studies. One example of the use of ocrelizumab use in aggressive MS showed the possibility of action on the leptomeningeal folliculi, seen at contract-enhancing MRI images.
Insights
Anti-B-cell therapies, such as ocrelizumab, are effective for multiple sclerosis (MS). This anti-CD20 antibody shows clinical and MRI benefits in relapsing MS and primary progressive MS (PPMS), even impacting leptomeningeal changes.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Anti-B-cell therapies targeting CD20 are emerging treatments for multiple sclerosis (MS).
- Ocrelizumab, an anti-CD20 monoclonal antibody, has demonstrated efficacy in clinical trials.
Purpose of the Study:
- To review the clinical and MRI efficacy of ocrelizumab in multiple sclerosis.
- To highlight the potential of ocrelizumab in aggressive MS and its effect on leptomeningeal changes.
Main Methods:
- Review of three phase III clinical studies evaluating ocrelizumab in MS.
- Case example of ocrelizumab use in aggressive MS with MRI analysis.
Main Results:
- Ocrelizumab demonstrated clinical and MRI efficacy in both relapsing MS and primary progressive MS (PPMS).
- The use of ocrelizumab in aggressive MS showed potential effects on leptomeningeal folliculi visualized by contrast-enhancing MRI.
Conclusions:
- Ocrelizumab is a clinically effective anti-CD20 therapy for multiple sclerosis, including PPMS.
- Ocrelizumab may influence pathological processes in aggressive MS, such as leptomeningeal inflammation.
Related Concept Videos
01:18Nucleophilic Addition to the Carbonyl Group: General Mechanism
A stronger nucleophile can directly attack the electrophilic center, the carbonyl carbon. The HOMO orbital of the nucleophile interacts with the LUMO (π* antibonding) orbital present on the carbonyl carbon. This interaction breaks the π bond and shifts the π...
01:28Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
01:23Local Anesthetics: Mechanism of Action
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
01:17Radical Anti-Markovnikov Addition to Alkenes: Mechanism
The mechanism starts with chain initiation, which involves two steps. In the first chain initiation step, a weak peroxide bond is homolytically cleaved upon mild heating to form two alkoxy radicals. In the second initiation step, a hydrogen atom is abstracted by the alkoxy...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...